Patents Represented by Attorney Leanne C. Incyte Pharmaceuticals, Inc. Price
  • Patent number: 6143544
    Abstract: The invention provides a new human lysophospholipase (JHLP) and polynucleotides which identify and encode IHLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating inflammation and disorders associated with expression of IHLP.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: November 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley, Lynn E. Murry
  • Patent number: 6136955
    Abstract: The present invention provides a human SMT3-like protein (HSMTH) and polynucleotides which identify and encode HSMTH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing HSMTH and for treating or preventing disorders associated with expression of HSMTH.
    Type: Grant
    Filed: October 14, 1998
    Date of Patent: October 24, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah
  • Patent number: 6090377
    Abstract: The present invention provides novel monocyte activating cytokine (MAC) and a polynucleotide encoding MAC. The invention also provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MAC. The invention also provides for the production and use of substantially purified MAC in pharmaceutical compositions for the treatment of cancer and disease of the immune system. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding MAC and antibodies which specifically bind to MAC.
    Type: Grant
    Filed: July 28, 1998
    Date of Patent: July 18, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Roger Coleman, Janice Au-Young, Lynn E. Murry
  • Patent number: 6074844
    Abstract: The invention provides two new human membrane fusion proteins (SYTAX1 or SYTAX2) and polynucleotides which identify and encode SYTAX1 or SYTAX2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of SYTAX1 or SYTAX2.
    Type: Grant
    Filed: June 11, 1997
    Date of Patent: June 13, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley
  • Patent number: 6033893
    Abstract: The invention provides a new human cathepsin (LCAP) and polynucleotides which identify and encode LCAP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of LCAP.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: March 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Karl J. Guegler, Neil C. Corley, Purvi Shah
  • Patent number: 6025464
    Abstract: The invention provides two new WD-40 proteins (WDPro) and polynucleotides which identify and encode WDPro. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of WDPro.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: February 15, 2000
    Assignee: Incyte Pharmaceutials, Inc.
    Inventors: Olga Bandman, Preeti Lal, Neil C. Corley
  • Patent number: 6018028
    Abstract: The present invention provides polynucleotides which identify and encode novel human proteasome subunit proteins. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding PSUB. The invention also provides for the use of substantially purified PSUB, antagonists, and in pharmaceutical compositions for the treatment of diseases associated with the expression of PSUB. Additionally, the invention provides for the use of antisense molecules to PSUB in pharmaceutical compositions for treatment of diseases associated with the expression of PSUB. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding PSUB or anti-PSUB antibodies which specifically bind to PSUB.
    Type: Grant
    Filed: August 13, 1998
    Date of Patent: January 25, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Janice Au-Young, Jennifer L. Hillman, Surya K. Goli
  • Patent number: 6015672
    Abstract: The invention provides a human Rab-specific guanine-nucleotide dissociation inhibitor (RGDI) and polynucleotides which identify and encode RGDI. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of RGDI.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: January 18, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Henry Yue, Neil C. Corley, Preeti Lal
  • Patent number: 5998373
    Abstract: The invention provides a human carboxypeptidase inhibitor (CARIN) and polynucleotides which identify and encode CARIN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of CARIN.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: December 7, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal
  • Patent number: 5986064
    Abstract: The present invention provides a human tumor-associated Kazal inhibitor (HuKI) and polynucleotides which identify and encode HuKI. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of HuKI, as well as diagnostic assays.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: November 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Karl J. Guegler, Purvi Shah
  • Patent number: 5976528
    Abstract: The present invention provides a human glutathione S-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGST and a method for producing HGST. The invention also provides for agonists, antibodies, or antagonists specifically binding HGST, and their use, in the prevention and treatment of cancer and other diseases associated with the expression of HGST. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGST for the treatment of cancer and other diseases associated with the expression of HGST. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGST.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Surya K. Goli, Jennifer L. Hillman
  • Patent number: 5976801
    Abstract: The invention provides two human reticulocalbin isoforms designated individually as RCN .gamma. and RCN .delta. and collectively as RCN, and polynucleotides which identify and encode RCN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of RCN.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharamceuticals, Inc.
    Inventors: Olga Bandman, Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah
  • Patent number: 5955305
    Abstract: The present invention provides a human retinoid binding protein (Hu-RBP) and polynucleotides which identify and encode Hu-RBP. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of Hu-RBP, as well as diagnostic assays.
    Type: Grant
    Filed: April 28, 1997
    Date of Patent: September 21, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Preeti Lal, Joanne R. Petithory
  • Patent number: 5952177
    Abstract: The invention provides a human cytosolic isocitrate dehydrogenase (HCID) and polynucleotides which identify and encode HCID. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating disorders associated with expression of HCID.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: September 14, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Preeti Lal, Neil C. Corley, Janice Au-Young
  • Patent number: 5948641
    Abstract: The present invention provides a metal response element binding protein (MERESP) and polynucleotides which identify and encode MERESP. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of MERESP.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: September 7, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Purvi Shah, Neil C. Corley
  • Patent number: 5942399
    Abstract: The invention provides a human amino acid permease homolog (AAPH) and polynucleotides which identify and encode AAPH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of AAPH.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: August 24, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Henry Yue, Neil C. Corley
  • Patent number: 5935812
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human GTP binding protein gamma-3 (HGPG) and HGPG itself. The invention provides for genetically engineered expression vectors, host cells containing the vector and a method for producing HGPG. The invention also provides a method for identifying pharmaceutical compositions inhibiting the expression and activity of HGPG and for the use of such compositions for the treatment of cancer. The invention also provides diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HGPG or anti-HGPG antibodies which specifically bind to HGPG in normal or diseased tissues.
    Type: Grant
    Filed: September 18, 1996
    Date of Patent: August 10, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli, Lynn E. Murry
  • Patent number: 5935813
    Abstract: The present invention provides a novel human C-type lectin (human PAP-2) and polynucleotides which identify and encode human PAP-2. The invention also provides expression vectors, host cells, agonists, antibodies or antagonists. The invention also provides methods for treating or preventing diseases associated with expression of human PAP-2.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: August 10, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Surya K. Goli
  • Patent number: 5928923
    Abstract: The invention provides a human short-chain dehydrogenase (HSCD) and polynucleotides which identify and encode HSCD. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HSCD.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: July 27, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Neil C. Corley
  • Patent number: 5919655
    Abstract: The present invention provides a human phospholemman homolog protein (HPLMH) and polynucleotides which identify and encode HPLMH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPLMH. The invention also provides for the use of HPLMH, and antibodies, or agonists or antagonists specifically binding HPLMH, in the prevention and treatment of diseases associated with expression of HPLMH. Additionally the invention provides for the use of antisense molecules to polynucleotides encoding HPLMH for the treatment of diseases associated with the expression of HPLMH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPLMH.
    Type: Grant
    Filed: October 25, 1996
    Date of Patent: July 6, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Jennifer L. Hillman